Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Arsanis inks deal for ASN300 program candidates
August 2018
SHARING OPTIONS:

WALTHAM, Mass. & VIENNA—Clinical-stage biopharmaceutical company Arsanis Inc. and BB200 LLC, a portfolio company of Bravos Biosciences LLC, have announced a licensing agreement. Under this deal, BB200 will be granted an exclusive, worldwide preclinical development license and an option to a clinical development and commercialization license to select monoclonal antibodies targeting K. pneumoniae, including lead candidate ASN-5. BB200 has the right to conduct additional preclinical development activities on licensed Arsanis monoclonal antibodies within the ASN300 program, with the option of entering into an exclusive global development and commercial license. Arsanis will retain the rights to all other monoclonal antibodies in its ASN300 program. This is the second agreement Arsanis has established recently with a Bravos company, having announced a similar deal with the subsidiary BB100 LLC centered on its ASN200 program.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.